Newswise — A recent University of Kentucky Markey Cancer Center study sheds light on how the environmental pollutant perfluorooctanesulfonic acid (PFOS) may affect our intestines and possibly increase the risk of developing colorectal cancer.
Published in Chemosphere, the research study led by Josiane Tessmann, Ph.D., a postdoctoral scholar in the laboratory of Yekaterina Zaytseva, Ph.D., is the first to show that long-term PFOS exposure can lead to changes in intestinal cells that are linked to the development of colorectal cancer.
PFOS belongs to a group of chemicals called PFAS (perfluoroalkyl and polyfluoroalkyl substances), which have been widely used in industrial applications and consumer products. Often referred to as “forever chemicals,” PFAS don’t break down easily and can stay in the environment and the human body for a long time. Exposure is linked to negative health outcomes including metabolic disorders, reduced immune responses and increased risk of cancer.
While previous research has linked PFOS to several types of cancer, including breast, liver, and kidney cancer, this study is the first to demonstrate a potential connection between PFOS exposure and colorectal cancer.
“Understanding how PFOS harms intestinal cells gives scientists new ideas on how to prevent these effects,” says Zaytseva, an associate professor in the UK College of Medicine Department of Toxicology and Cancer Biology. “This study opens up a new area of investigation that could change how we approach colorectal cancer prevention in communities with high PFOS exposure.”
Zaytseva added that these findings are especially important for Kentucky: PFAS chemicals are found in 90% of surface waters tested in our state, with PFOS one of the most common.
The study in mice found that PFOS exposure caused lowered levels of a ketogenic enzyme in the intestines called HMGCS2, which plays an important preventive role in several cancers, including colorectal cancer. At the same time, exposure increased levels of proteins that are linked to cancer growth. Zaytseva’s team also found similar changes in samples of human intestinal cells when they were exposed to PFOS.
The study results suggest that certain dietary changes might help protect intestines from the harmful effects of PFOS exposure. Future studies will focus on testing dietary interventions including the supplement beta-hydroxybutyrate, which is naturally produced in the body when HMGCS2 is present, to see if they can prevent PFOS-induced changes in normal intestinal tissues.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA177558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
UK HealthCare is the hospitals and clinics of the University of Kentucky. But it is so much more. It is more than 10,000 dedicated health care professionals committed to providing advanced subspecialty care for the most critically injured and ill patients from the Commonwealth and beyond. It also is the home of the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, a Level IV Neonatal Intensive Care Unit that cares for the tiniest and sickest newborns, the region’s only Level 1 trauma center and Kentucky’s top hospital ranked by U.S. News & World Report.
As an academic research institution, we are continuously pursuing the next generation of cures, treatments, protocols and policies. Our discoveries have the potential to change what’s medically possible within our lifetimes. Our educators and thought leaders are transforming the health care landscape as our six health professions colleges teach the next generation of doctors, nurses, pharmacists and other health care professionals, spreading the highest standards of care. UK HealthCare is the power of advanced medicine committed to creating a healthier Kentucky, now and for generations to come.
RSS